We are live on
!
Find out more
TLP
Tri Locum Partners Portfolio holdings
AUM
$713M
1-Year Est. Return
68.92%
This Fund
S&P 500
This Quarter
Est. Return
+18.45%
1 Year Est. Return
+68.92%
3 Year Est. Return
+377.81%
5 Year Est. Return
+1,289.15%
10 Year Est. Return
–
AUM
$364M
AUM Growth
+$120M
(+49%)
Cap. Flow
+$104M
Cap. Flow
% of AUM
28.62%
Top 10 Holdings %
Top 10 Hldgs %
53.87%
Holding
72
New
21
Increased
11
Reduced
9
Closed
31
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Neurocrine Biosciences
NBIX
|
+$19.9M |
| 2 |
Biogen
BIIB
|
+$19.2M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
+$19M |
| 4 |
GSK
GSK
|
+$15.5M |
| 5 |
CTLT
CATALENT, INC.
CTLT
|
+$12.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CCXI
ChemoCentryx, Inc.
CCXI
|
+$13.5M |
| 2 |
Evolent Health
EVH
|
+$9.98M |
| 3 |
BLU
BELLUS Health Inc.
BLU
|
+$9.77M |
| 4 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
+$8.88M |
| 5 |
TCDA
Tricida, Inc. Common Stock
TCDA
|
+$7.08M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 93.38% |
| 2 | Consumer Staples | 2.67% |
| 3 | Financials | 0.17% |
| 4 | Industrials | 0% |
| 5 | Materials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Eli Lilly
LLY
$1.05T
| $34M | 9.33% |
105,170
+35,503
| +51% | +$11.2M |
|
|
2
Biogen
BIIB
$30.4B
| $24.2M | 6.64% |
+90,551
| New | +$19.2M |
|
3
argenx
ARGX
$53.8B
| $22.6M | 6.22% |
64,152
-18,583
| -22% | -$6.88M |
|
|
4
Neurocrine Biosciences
NBIX
$17.2B
| $20.9M | 5.73% |
+196,390
| New | +$19.9M |
|
|
5
Regeneron Pharmaceuticals
REGN
$70.9B
| $20.7M | 5.69% |
+30,115
| New | +$19M |
|
|
CTLT
6
DELISTED
CATALENT, INC.
CTLT
| $17M | 4.67% |
235,320
+127,079
| +117% | +$12.6M |
|
7
Guardant Health
GH
$20.7B
| $15.4M | 4.22% |
285,948
+93,640
| +49% | +$4.81M |
|
8
Jazz Pharmaceuticals
JAZZ
$15.5B
| $14.2M | 3.9% |
106,528
+49,165
| +86% | +$7.48M |
|
9
Edwards Lifesciences
EW
$49.4B
| $14.1M | 3.88% |
171,082
-11,572
| -6% | -$1.11M |
|
10
Stevanato
STVN
$5.23B
| $13.1M | 3.59% |
771,933
-117,563
| -13% | -$1.98M |
|
|
FLNA
11
CALL
Filana Therapeutics
FLNA
$51.2M
| $12.1M | 3.32% |
+289,300
| New | +$7.81M |
|
|
12
GSK
GSK
$104B
| $12.1M | 3.31% |
+409,503
| New | +$15.5M |
|
13
Bausch + Lomb
BLCO
$5.8B
| $10.7M | 2.95% |
+700,525
| New | +$11.1M |
|
|
MRTX
14
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $10.6M | 2.9% |
+151,534
| New | +$11.2M |
|
15
Sarepta Therapeutics
SRPT
$1.82B
| $10.6M | 2.9% |
+95,445
| New | +$9.62M |
|
16
SkinHealth Systems
SKIN
$109M
| $9.73M | 2.67% |
825,109
-89,085
| -10% | -$1.13M |
|
17
Allogene Therapeutics
ALLO
$618M
| $8.47M | 2.32% |
784,133
+512,010
| +188% | +$6.96M |
|
|
RXDX
18
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $7.29M | 2% |
123,599
-194,159
| -61% | -$8.88M |
|
19
Maravai LifeSciences
MRVI
$1.07B
| $7.17M | 1.97% |
+280,811
| New | +$7.05M |
|
|
AKRO
20
DELISTED
Akero Therapeutics
AKRO
| $7.13M | 1.96% |
+209,248
| New | +$3.2M |
|
21
Celldex Therapeutics
CLDX
$2.77B
| $6.71M | 1.84% |
238,569
+106,421
| +81% | +$3.26M |
|
22
Coherus Oncology
CHRS
$216M
| $6.12M | 1.68% |
636,943
+260,457
| +69% | +$2.64M |
|
|
KZR
23
DELISTED
Kezar Life Sciences
KZR
| $6.11M | 1.68% |
70,973
+20,539
| +41% | +$2M |
|
|
ATXS
24
DELISTED
Astria Therapeutics
ATXS
| $5.71M | 1.57% |
+631,579
| New | +$4.23M |
|
25
Natera
NTRA
$38.9B
| $5.7M | 1.56% |
+129,955
| New | +$6.19M |
|
Similar funds
DCM
AMPWP
DCM
IWP
LS
PCS
ACGDR
GEA
Tri Locum Partners's Q3 2022 Portfolio in Review
As of Q3 2022, Tri Locum Partners held 72 positions worth $364M, up 49% from $244M the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Tri Locum Partners deployed $104M of net new capital in Q3 2022, opening 21 new positions and adding to 11 existing holdings. Its largest new stake was Neurocrine Biosciences: 196,390 shares worth $20.9M.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 89% a quarter earlier, followed by Consumer Staples and Financials.
On the sell side, the largest reduction was BELLUS Health Inc., an estimated $9.77M trimmed.
- Tri Locum Partners's largest Q3 2022 buy was Neurocrine Biosciences: 196,390 shares worth $20.9M.
- Tri Locum Partners added most to CATALENT, INC. in Q3 2022, an estimated $12.6M increase.
- Tri Locum Partners's biggest Q3 2022 reduction was BELLUS Health Inc., cutting an estimated $9.77M.
- Tri Locum Partners fully exited ChemoCentryx, Inc. in Q3 2022, selling an estimated $13.5M.
- Tri Locum Partners's ten largest holdings make up 54% of its $364M portfolio in Q3 2022.
- Tri Locum Partners opened 21 new positions and closed 31 in Q3 2022.
- Tri Locum Partners's portfolio value rose 49% quarter-over-quarter to $364M.
Based on Tri Locum Partners's 13F filing for Q3 2022, filed 14 Nov 2022.